Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood, tears and saliva: the hunt for Migraine's hidden signature

NCT ID NCT07832032

NEW Knowledge-focused Sponsor: Nordlandssykehuset HF Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 21, 2026 · Last updated Sep 21, 2026

Summary

Researchers want to know whether migraine leaves a measurable biological trace in the body. They will collect blood, saliva and tear fluid from 60 adults with episodic migraine, both during an attack and between attacks, and compare the samples with those from people who do not get migraines. Participants who have an attack during the workday will come in for immediate sampling and then receive rimegepant, a fast-dissolving migraine drug. The goal is to identify proteins and genetic fragments that could one day serve as biological markers for migraine.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
rimegepant, an oral CGRP receptor antagonist migraine drug
What this could lead to
If researchers find reliable biological signals during migraine attacks, doctors could one day diagnose migraine with a simple sample instead of relying on symptom descriptions alone.
What could go wrong
This is a small study of 60 people that only observes biological changes. It cannot prove these markers cause migraine or that they would work as a diagnostic test in the wider population.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The individuals eligible for inclusion in this study are employees at Nordland hospital who sometimes use to experience migraine attacks at work during daytime.

Ages

18 to 55 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Informed and written consent. 2. Men and women, between 18 and 55 years of age. 3. Master a Scandinavian language at level sufficient to fully understand the written and verbal study information. 4. Migraine, with or without aura, fulfilling the International Classification of Headache Disorders (ICHD) III criteria for episodic migraine at time of inclusion. They must report at least 1 attack per month requiring the use of acute medication. 5. Consent to fill out a headache diary for up to 6 months. Exclusion Criteria: 1. Pregnancy 2. Smoking 3. The subject is unable to differentiate migraine from other concomitant headaches 4. The subject having chronic migraine or other chronic pain conditions 5. The subject has severe psychiatric disorders (including depression), substance abuse, severe somatic disorders, and any medical condition that could alter tear and saliva production. 6. Eye disorders that cause pain, require medication or affect tear production. 7. Subjects using tricyclic antidepressant or CGRP antagonists. 8. Contraindication for gepants.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Migraine are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes insipidus migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Migraine

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Departement of Neurology, NLSH HF

    Bodø, 8005, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.